Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis
- 1 September 1999
- journal article
- Published by Elsevier in Kidney International
- Vol. 56 (3) , 1078-1083
- https://doi.org/10.1046/j.1523-1755.1999.00613.x
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in manThe Lancet, 1992
- Autoantibody against oxidised LDL and progression of carotid atherosclerosisThe Lancet, 1992
- Role of oxidized low density lipoprotein in atherogenesis.Journal of Clinical Investigation, 1991
- Role of vitamin E in preventing the oxidation of low-density lipoproteinThe American Journal of Clinical Nutrition, 1991
- Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man.Journal of Clinical Investigation, 1989
- Malondialdehyde-Altered Protein Occurs in Atheroma of Watanabe Heritable Hyperlipidemic RabbitsScience, 1988
- Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis.Proceedings of the National Academy of Sciences, 1987
- Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low density lipoprotein.Proceedings of the National Academy of Sciences, 1985
- Enhanced macrophage degradation of biologically modified low density lipoprotein.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1983
- Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins.Proceedings of the National Academy of Sciences, 1981